News | November 20, 2014

Oxford University Study at AHA Shows Extent of Vascular Damage Caused by Smoking

The researchers found that smokers were 12 times more likely than non-smokers to develop an abdominal aortic aneurism

Oxford clinical study, American Heart Association, abdominal aortic aneurism

Photo courtesy of Portable Networks Graphics

November 20, 2014 — Oxford University researchers presented data that reveal the extent to which smoking causes silent but deadly damage to health at the annual scientific meeting of the American Heart Association (AHA).

Working with Life Line Screening’s database of several million U.S. adults, Oxford researchers looked at people without symptoms who attended the company’s screening service. The researchers found that smokers were 12 times more likely than non-smokers to develop an abdominal aortic aneurism.

They also found that rates of aortic aneurysms were 12 times higher, leg circulation problems seven times higher and carotid artery narrowing five times higher in current smokers compared to those who have never smoked. 

“Smokers are much more likely to develop life-threatening vascular problems,” said Richard Bulbulia, M.D., who led the study.

The researchers used screening data from 3.1 million U.S. adults who underwent four non-invasive procedures: ultrasound of the carotid artery, ultrasound of the aorta, an ECG to help determine stroke risk and blood pressure in the arms and legs to assess circulation. The results are being presented today at the AHA Annual Meeting in Chicago and show the importance of cigarette smoking as a risk factor for these asymptomatic, silent conditions.

The work will also help determine the importance of high cholesterol, high blood pressure and obesity for these ‘silent’ vascular conditions, helping to prevent significant disease and premature death from vascular disease.

This work is funded by a Henry Goodger Fellowship, and CTSU receives core funding from the British Heart Foundation, UK Medical Research Council and Cancer Research UK.

For more information: www.ctsu.ox.ac.uk

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init